A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Investigational new drugs

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10637-012-9863-1PMID 22847785PMCID PMC3646991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients

  2011cited by this paper
• Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

  2011cited by this paper
• A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503

  2010cited by this paper
• Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma.

  2009cited by this paper
• Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group.

  2009cited by this paper
• Inhibitory mechanisms of heterocyclic carboxaldehyde thiosemicabazones for two forms of human ribonucleotide reductase.

  2009cited by this paper
• A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells

  2008cited by this paper
• A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium

  2007cited by this paper
• Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.

  2007cited by this paper
• Production of a Monoclonal Antibody Against the hRRM2 Subunit of Ribonucleotide Reductase and Immunohistochemistry Study of Human Cancer Tissues

  2006cited by this paper
• A Ferrous-triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase

  2006cited by this paper
• Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreas.

  2006cited by this paper
• Iron chelators as therapeutic iron depletion agents

  2006cited by this paper
• Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

  2005cited by this paper
• A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer

  2004influential reference
• RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine

  2004cited by this paper
• Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.

  2004cited by this paper
• Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.

  2003cited by this paper
• Gemcitabine in transitional cell carcinoma of the urothelium

  2003cited by this paper
• Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.

  2003cited by this paper
• Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma.

  2003cited by this paper
• Role of Gemcitabine in the Treatment of Advanced and Metastatic Breast Cancer

  2003cited by this paper
• Gemcitabine in transitional cell carcinoma of the urothelium

  2003cited by this paper
• Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia.

  2002cited by this paper
• Review of gemcitabine in biliary tract carcinoma.

  2002cited by this paper
• Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

  2002cited by this paper
• Phase I and pharmacokinetic study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) using a single intravenous dose schedule

  2002cited by this paper
• Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells.

  2002cited by this paper
• Second-line treatment of ovarian cancer with single-agent gemcitabine.

  2002cited by this paper
• Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)

  2002cited by this paper
• Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit.

  2001cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• Triapine (3-aminopyridine-2-carboxaldehyde- thiosemicarbazone): A potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity.

  2000cited by this paper
• Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer.

  1999cited by this paper
• Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer.

  1999cited by this paper
• Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.

  1999cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells.

  1997cited by this paper
• Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones.

  1994cited by this paper
• Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

  1992cited by this paper
• Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.

  1992cited by this paper
• Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine.

  1990cited by this paper
• S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs.

  1990cited by this paper
• Differential modulation of 1-beta-D-arabinofuranosylcytosine metabolism by hydroxyurea in human leukemic cell lines.

  1988cited by this paper
• Increased activation of 1-beta-D-arabinofuranosylcytosine by hydroxyurea in L1210 cells.

  1980cited by this paper
• Inhibition of deoxyribonucleotide synthesis by pyridine carboxaldehyde thiosemicarbazones.

  1971cited by this paper
• Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas.

  1970cited by this paper

• Synthesis of 5-hydroxyisatin thiosemicarbazones, spectroscopic investigation, protein-ligand docking, and in vitro anticancer activity.

  2024cites this paper
• Antiproliferative Activity and DNA Interaction Studies of a Series of N4,N4-Dimethylated Thiosemicarbazone Derivatives

  2023cites this paper
• Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer.

  2023cites this paper
• The Role of Iron in DNA and Genomic Instability in Cancer, a Target for Iron Chelators That Can Induce ROS

  2022cites this paper
• Screening of traditional Chinese medicine monomers as ribonucleotide reductase M2 inhibitors for tumor treatment

  2022cites this paper
• New Iron Metabolic Pathways and Chelation Targeting Strategies Affecting the Treatment of All Types and Stages of Cancer

  2022cites this paper
• Mechanistic Insights of Chelator Complexes with Essential Transition Metals: Antioxidant/Pro-Oxidant Activity and Applications in Medicine

  2022cites this paper
• Modulation of Intracellular Copper Levels as the Mechanism of Action of Anticancer Copper Complexes: Clinical Relevance

  2021cites this paper
• Coumarin-Based Triapine Derivatives and Their Copper(II) Complexes: Synthesis, Cytotoxicity and mR2 RNR Inhibition Activity

  2021cites this paper
• Reversing oncogenic transformation with iron chelation

  2021cites this paper
• Inhibiting RRM2 to enhance the anticancer activity of chemotherapy.

  2020cites this paper
• Triapine Derivatives Act as Copper Delivery Vehicles to Induce Deadly Metal Overload in Cancer Cells

  2020cites this paper
• Division of Cancer Treatment and Diagnosis

  2020cites this paper
• Novel Triapine Derivative Induces Copper-Dependent Cell Death in Hematopoietic Cancers.

  2019cites this paper
• Structural analysis and biological functionalities of iron(III)– and manganese(III)–thiosemicarbazone complexes: in vitro anti-proliferative activity on human cancer cells, DNA binding and cleavage studies

  2019cites this paper
• EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness

  2019cites this paper
• Synthesis and biochemical study on the effect of a novel gallium complex on tumor cell Invasion and matrix metalloproteinase activity in vitro.

  2017cites this paper
• Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?

  2017cites this paper
• LC–MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma

  2017cites this paper
• Selenotriapine – An isostere of the most studied thiosemicarbazone with pronounced pro-apoptotic activity, low toxicity and ability to challenge phenotype reprogramming of 3-D mammary adenocarcinoma tumors

  2017cites this paper
• A Regioselective Multicomponent Cascade to Access Thiosemicarbazone–fused Thiazinones: Scope, Structure Elucidation and Gram Scale Synthesis

  2017cites this paper
• Determination of triapine, a ribonucleotide reductase inhibitor, in human plasma by liquid chromatography tandem mass spectrometry.

  2015cites this paper
• In Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I Metabolites

  2015cites this paper
• G2/M Cell Cycle Arrest and Tumor Selective Apoptosis of Acute Leukemia Cells by a Promising Benzophenone Thiosemicarbazone Compound

  2015cites this paper
• 2-Butyl-4-chloroimidazole based substituted piperazine-thiosemicarbazone hybrids as potent inhibitors of Mycobacterium tuberculosis.

  2014cites this paper
• Using Drosophila melanogaster To Identify Chemotherapy Toxicity Genes

  2014cites this paper
• Expanding horizons in iron chelation and the treatment of cancer: role of iron in the regulation of ER stress and the epithelial-mesenchymal transition.

  2014cites this paper
• Development of quantitative bioanalytical methods for the pharmacological studies of anti-cancer drugs

  2013cites this paper
• Targeting ribonucleotide reductase for cancer therapy

  2013cites this paper
• 核糖核苷酸还原酶和非小细胞肺癌

  2012cites this paper
• Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer

  2011cites this paper